Evidence map›Paper›PMID 28376153›Full record

ArticleJournal of the National Cancer Institute2017

Evidence for a Mesothelial Origin of Body Cavity Effusion Lymphomas.

David Sanchez-Martin, Thomas S Uldrick, Hyeongil Kwak, Hidetaka Ohnuki, Mark N Polizzotto, Christina M Annunziata, Mark Raffeld, Kathleen M Wyvill, Karen Aleman, Victoria Wang and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. HIV-Associated Cancers and Related Diseases.The New England journal of medicine · 2018
    Review
  6. Human Herpesvirus 8 and Lymphoproliferative Disorders.Mediterranean journal of hematology and infectious diseases · 2018
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

David Sanchez-MartinLaboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD, USA.
Thomas S UldrickHIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA.
Hyeongil KwakLaboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD, USA.
Hidetaka OhnukiLaboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD, USA.
Mark N PolizzottoHIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA.
Christina M AnnunziataWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Mark RaffeldLaboratory of Pathology, National Cancer Institute, Bethesda, MD, USA.
Kathleen M WyvillHIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA.
Karen AlemanHIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA.
Victoria WangHIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA.
Vickie A MarshallCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Denise WhitbyCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Robert YarchoanHIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA.
Giovanna TosatoLaboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD, USA.
National Cancer Institute · USCenter for Cancer Research · USNational Institutes of Health · USLeidos (United States) · US

Funding

Clinical Trials of Patients with AIDS-Related MalignanciesZIABC010888 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI YARCHOAN, ROBERT · 2009 to 2025
$20.6M
A Role for KSHV in the Pathogenesis of MalignanciesZIASC010356 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI TOSATO, GIOVANNA · 2009 to 2025
$7.7M
6 · The paper itself

Abstract

Background: Primary effusion lymphoma (PEL) is a Kaposi's sarcoma herpes virus (KSHV)-induced lymphoma that typically arises in body cavities of HIV-infected patients. PEL cells are often co-infected with Epstein-Barr virus (EBV). "PEL-like" lymphoma is a KSHV-unrelated lymphoma that arises in body cavities of HIV-negative patients. "PEL-like" lymphoma is sometimes EBV positive. The derivation of PEL/"PEL-like" cells is unclear. Methods: Mesothelial cells were cultured from body cavity effusions of 23 patients. Cell proliferation, cytokine secretion, marker phenotypes, KSHV/EBV infection, and clonality were evaluated by standard methods. Gene expression was measured by quantitative polymerase chain reaction and immunoblotting. A mouse model of PEL (3 mice/group) was used to evaluate tumorigenicity. Results: We found that the mesothelia derived from six effusions of HIV-infected patients with PEL or other KSHV-associated diseases contained rare KSHV + or EBV + mesothelial cells. After extended culture (16-17 weeks), some mesothelial cells underwent a trans-differentiation process, generating lymphoid-type CD45 + /B220 + , CD5 + , CD27 + , CD43 + , CD11c + , and CD3 - cells resembling "B1-cells," most commonly found in mouse body cavities. These "B1-like" cells were short lived. However, long-term KSHV + EBV - and EBV + KSHV - clonal cell lines emerged from mesothelial cultures from two patients that were clonally distinct from the monoclonal or polyclonal B-cell populations found in the patients' original effusions. Conclusions: Mesothelial-to-lymphoid transformation is a newly identified in vitro process that generates "B1-like" cells and is associated with the emergence of long-lived KSHV or EBV-infected cell lines in KSHV-infected patients. These results identify mesothelial cultures as a source of PEL cells and lymphoid cells in humans.

Indexed as

AdultAgedAnimalsDisease Models, AnimalEpithelial-Mesenchymal TransitionEpitheliumEpstein-Barr Virus InfectionsHerpesviridae InfectionsHerpesvirus 4, HumanHerpesvirus 8, HumanHumansLymphoma, Primary EffusionMaleMiceMice, Inbred NODMice, SCID

Identifiers

PMID28376153
PMCPMC6059237
OpenAlexW2599890190

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.